DexCom Reiterated at Neutral

We reaffirm our Neutral recommendation on DexCom Inc (DXCM), a prominent player in the continuous glucose monitoring market. Second-quarter fiscal 2010 loss per share of 20 cents matched the Zacks Consensus Estimate while revenues soared 75% year-over-year riding on solid product sales. DexCom is a medical devices company focused on the design, development and commercialization of [...]